In this double-blind comparative study, AJG533 (elobixibat) 10 mg or AJG533 placebo was
orally administered once daily before meals for 12 weeks in patients with chronic
constipation, and the primary endpoint was the change from Week 2 of the observation period
in the number of complete spontaneous bowel movements (CSBM) at Week 12 of the treatment
period. The primary endpoint was the change in the number of complete spontaneous bowel
movements (CSBM) from Week 2 of the observation period.